K. Orford

发表

Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation

D. Scadden, K. Orford, David T. Scadden, 2008, Nature Reviews Genetics.

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation

A. Tolcher, K. Papadopoulos, A. Patnaik, 2014, Journal of clinical pharmacology.

Evaluation of the Effects of Food on the Single‐Dose Pharmacokinetics of Trametinib, a First‐in‐Class MEK Inhibitor, in Patients with Cancer

A. Tolcher, P. LoRusso, K. Papadopoulos, 2013, Journal of clinical pharmacology.

Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM).

G. Linette, J. Wolchok, J. Sosman, 2014 .

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

R. Bernards, C. Atreya, J. Schellens, 2014 .

The minimal impact of food on the pharmacokinetics of ridaforolimus

J. Wagner, M. Trucksis, D. Panebianco, 2012, Cancer Chemotherapy and Pharmacology.

Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib (GSK436) in combination with the MEK inhibitor trametinib (GSK212) in patients with BRAFV600 mutant colorectal cancer (CRC).

C. Atreya, R. Kurzrock, D. Ryan, 2013 .

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer

A. Tolcher, K. Papadopoulos, A. Patnaik, 2012, Cancer Chemotherapy and Pharmacology.

Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers

M. Morris, R. A. Morrison, K. Orford, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Concomitant oral and intravenous pharmacokinetics of trametinib, a MEK inhibitor, in subjects with solid tumours.

D. Ouellet, R. A. Morrison, K. Orford, 2014, British journal of clinical pharmacology.

Differential H3K4 methylation identifies developmentally poised hematopoietic genes.

P. Park, P. Kharchenko, W. Lai, 2008, Developmental cell.

Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin*

Stephen W. Byers, S. Byers, J. P. Jensen, 1997, The Journal of Biological Chemistry.

Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors

Suzanne F. Jones, J. Bendell, H. Burris, 2015, Clinical pharmacology in drug development.

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

A. Tolcher, N. Ibrahim, K. Papadopoulos, 2014, Cancer Chemotherapy and Pharmacology.

Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest

S. Byers, K. Orford, Caroline C. Orford, 1999, The Journal of cell biology.

Exogenous Expression of b -Catenin Regulates Contact Inhibition, Anchorage-independent Growth, Anoikis, and Radiation-induced Cell Cycle Arrest

S. Byers, K. Orford, Caroline C. Orford, 1999 .

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin.

S. Byers, J. P. Jensen, A. Weissman, 1997, The Journal of biological chemistry.

A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors

M. Voss, A. DeMichele, F. Meric-Bernstam, 2021, Clinical Cancer Research.

Genome-wide Map of Nuclear Protein Degradation Shows NCoR1 Turnover as a Key to Mitochondrial Gene Regulation

X. Liu, D. Scadden, D. Dombkowski, 2013, Cell.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma

A. Younes, M. Bennett, K. Orford, 2015 .

Phase 1 Study of CB-839, a First-in-Class, Orally Administered Small Molecule Inhibitor of Glutaminase in Patients with Relapsed/Refractory Leukemia

I. Flinn, M. Konopleva, M. Maris, 2015 .

Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.

C. Porta, R. Figlin, T. Powles, 2022, JAMA oncology.

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic

C. Porta, R. Figlin, R. Motzer, 2021 .

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC).

M. Voss, A. DeMichele, F. Meric-Bernstam, 2016 .

Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial.

R. Motzer, J. Hsieh, Chung-Han Lee, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.

R. Srinivasan, M. Voss, A. DeMichele, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours

J. Schellens, A. Robidoux, L. Cartee, 2014, Investigational New Drugs.

CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.

K. Papadopoulos, M. Bennett, S. Fu, 2017 .

Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.

K. Bachman, M. Motwani, J. Zou, 2014 .

Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).

C. Atreya, J. Schellens, J. Tabernero, 2015 .

Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis.

C. Atreya, R. Kurzrock, D. Ryan, 2014 .

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

C. Atreya, R. Kurzrock, D. Ryan, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus

W. Kraft, J. Wagner, M. Trucksis, 2012, Cancer Chemotherapy and Pharmacology.